<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">Prediabetes</z:e> and type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) are believed to be common and associated with a worse metabolic profile in patients with nonalcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease (NAFLD) </plain></SENT>
<SENT sid="1" pm="."><plain>However, no previous study has systematically screened this population </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We studied the prevalence and the metabolic impact of <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e> and T2DM in 118 patients with NAFLD </plain></SENT>
<SENT sid="3" pm="."><plain>The control group comprised 20 subjects without NAFLD matched for age, sex, and <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We measured 1) plasma <z:chebi fb="105" ids="17234">glucose</z:chebi>, insulin, and free fatty acid (FFA) concentration during an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test; 2) liver fat by magnetic resonance spectroscopy (MRS); 3) liver and muscle insulin sensitivity (euglycemic insulin clamp with 3-[(3)H]<z:chebi fb="105" ids="17234">glucose</z:chebi>); and 4) indexes of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (IR) at the level of the liver (HIR(i)= endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> production × fasting plasma insulin [FPI]) and adipose tissue (Adipo-IR(i)= fasting FFA × FPI) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">Prediabetes</z:e> and T2DM was present in 85% versus 30% in controls (P &lt; 0.0001), <z:hpo ids='HP_0000001'>all</z:hpo> unaware of having abnormal <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism </plain></SENT>
<SENT sid="6" pm="."><plain>NAFLD patients were IR at the level of the adipose tissue, liver, and muscle (<z:hpo ids='HP_0000001'>all</z:hpo> P &lt; 0.01-0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Muscle and liver insulin sensitivity were impaired in patients with NAFLD to a similar degree, whether they had <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e> or T2DM </plain></SENT>
<SENT sid="8" pm="."><plain>Only adipose tissue IR worsened in T2DM and correlated with the severity of muscle (r = 0.34; P &lt; 0.001) and hepatic (r = 0.57; P &lt; 0.0001) IR and <z:hpo ids='HP_0001397'>steatosis</z:hpo> by MRS (r = 0.35; P &lt; 0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Patients with NAFLD may benefit from early screening for T2DM, because the prevalence of abnormal <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism is much higher than previously appreciated </plain></SENT>
<SENT sid="10" pm="."><plain>Regardless of <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance status, severe IR is common </plain></SENT>
<SENT sid="11" pm="."><plain>In patients with T2DM, adipose tissue IR appears to play a major role in the severity of NAFLD </plain></SENT>
</text></document>